CorMedix (CRMD) director Alan W. Dunton awarded 30,453 restricted stock units

Rhea-AI Filing Summary

CorMedix Inc. director Alan W. Dunton received an equity award in the form of restricted stock units. On January 26, 2026, he was granted 30,453 restricted stock units of CorMedix common stock at a grant price of $0.00 per unit, increasing his beneficial ownership to 70,703 shares.

Each restricted stock unit represents the right to receive one share of common stock. The units will vest in full on January 26, 2027, provided he continues serving the company through the vesting date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DUNTON ALAN W

(Last) (First) (Middle)

C/O CORMEDIX INC.

389 INTERPACE PKWY, SUITE 450

(Street)

PARSIPPANY NJ 07054

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		A		30,453	A	$0.00(1)	70,703	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units issued on January 26, 2026. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units will vest in full on January 26, 2027, subject to continued service on the vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Beth Zelnick Kaufman, attorney-in-fact	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CorMedix Inc. (CRMD) disclose in this Form 4 filing?

CorMedix Inc. reported an equity award to director Alan W. Dunton. He received 30,453 restricted stock units of common stock that vest in full on January 26, 2027, subject to continued service.

How many CorMedix (CRMD) shares did Alan W. Dunton acquire in this transaction?

Alan W. Dunton was granted 30,453 restricted stock units of CorMedix common stock. These units were awarded at a grant price of $0.00 per unit as part of his director compensation package.

When do Alan W. Dunton’s CorMedix (CRMD) restricted stock units vest?

The restricted stock units granted to Alan W. Dunton will vest in full on January 26, 2027. Vesting is conditioned on his continued service with CorMedix through the vesting date.

What is Alan W. Dunton’s total CorMedix (CRMD) share ownership after this Form 4?

Following the grant, Alan W. Dunton beneficially owns 70,703 shares of CorMedix common stock. This figure reflects his holdings after receiving the 30,453 restricted stock units reported in the filing.

What type of security was granted to Alan W. Dunton by CorMedix (CRMD)?

CorMedix granted restricted stock units to director Alan W. Dunton. Each unit gives the right to receive one share of CorMedix common stock upon vesting, aligning his compensation with shareholder interests.

Was there any cash paid for the CorMedix (CRMD) shares in this Form 4?

No cash changed hands for this award. The 30,453 restricted stock units were granted to Alan W. Dunton at a stated price of $0.00 per share, typical for equity compensation grants.